123 related articles for article (PubMed ID: 7437329)
1. Evaluation of a new chromogenic assay for factor VII and its application in patients on oral anticoagulant treatment.
Avvisati G; ten Cate JW; van Wijk EM; Kahlé LH; Mariani G
Br J Haematol; 1980 Jun; 45(2):343-52. PubMed ID: 7437329
[TBL] [Abstract][Full Text] [Related]
2. Use of chromogenic peptide substrates in the determination of clotting factors II, VII, IX and X in normal plasma and in plasma of patients treated with oral anticoagulants.
van Dieijen-Visser MP; van Wersch J; Brombacher PJ; Rosing J; Hemker HC; van Dieijen G
Haemostasis; 1982; 12(3):241-55. PubMed ID: 7141303
[TBL] [Abstract][Full Text] [Related]
3. An assessment of an amidolytic assay for factor VII in the laboratory control of oral anticoagulants.
Poller L; Thomson JM; Bodzenta A; Easton AC; Latallo ZS; Chmielewska J
Br J Haematol; 1981 Sep; 49(1):69-75. PubMed ID: 7272230
[TBL] [Abstract][Full Text] [Related]
4. Coupled amidolytic assay for factor VII: its use with a clotting assay to determine the activity state of factor VII.
Seligsohn U; Osterud B; Rapaport SI
Blood; 1978 Nov; 52(5):978-88. PubMed ID: 698402
[TBL] [Abstract][Full Text] [Related]
5. An evaluation of chromogenic substrates in the control of oral anticoagulant therapy.
Latallo ZS; Thomson JM; Poller L
Br J Haematol; 1981 Feb; 47(2):307-18. PubMed ID: 7470395
[TBL] [Abstract][Full Text] [Related]
6. Oral anticoagulant control with a chromogenic substrate: calibration, precision and cost.
Famodu AA; Ingram GI
Clin Lab Haematol; 1982; 4(1):27-39. PubMed ID: 7067373
[TBL] [Abstract][Full Text] [Related]
7. Warfarin or acenocoumarol: which is better in the management of oral anticoagulants?
Barcellona D; Vannini ML; Fenu L; Balestrieri C; Marongiu F
Thromb Haemost; 1998 Dec; 80(6):899-902. PubMed ID: 9869157
[TBL] [Abstract][Full Text] [Related]
8. Immunoradiometric assays for human coagulation factor VII using polyclonal antibodies against the Ca(II)-dependent and Ca(II)-independent conformation.
Bom VJ; van Tilburg NH; Krommenhoek-van Es C; Bertina RM
Thromb Haemost; 1986 Dec; 56(3):343-8. PubMed ID: 2436334
[TBL] [Abstract][Full Text] [Related]
9. Biological properties of the thromboplastins and plasmas included in the ICTH/ICSH collaborative study on prothrombin time standardization.
Loeliger EA; van Halem-Visser LP
Thromb Haemost; 1979 Dec; 42(4):1115-27. PubMed ID: 542924
[No Abstract] [Full Text] [Related]
10. How to measure factor VII and factor VII activation.
Osterud B
Haemostasis; 1983; 13(3):161-8. PubMed ID: 6350121
[TBL] [Abstract][Full Text] [Related]
11. Control of anticoagulant therapy with a chromogenic substrate.
Kirchhof BR; Muller AD; Vermeer C; Hemker HC
Haemostasis; 1979; 8(1):1-7. PubMed ID: 456941
[TBL] [Abstract][Full Text] [Related]
12. Further evaluation of an automated amidolytic factor X assay in monitoring anti-vitamin K treatment.
van Wijk EM; Kahlé LH; Jeletich A; ten Cate JW
Scand J Haematol; 1982 Aug; 29(2):105-14. PubMed ID: 6813960
[TBL] [Abstract][Full Text] [Related]
13. Relationship between international normalized ratio values, vitamin K-dependent clotting factor levels and in vivo prothrombin activation during the early and steady phases of oral anticoagulant treatment.
D'Angelo A; Della Valle P; Crippa L; Fattorini A; Pattarini E; Viganò D'Angelo S
Haematologica; 2002 Oct; 87(10):1074-80. PubMed ID: 12368163
[TBL] [Abstract][Full Text] [Related]
14. Coagulation monitor based on serum migration through absorbent materials.
Wilson PE
Clin Chem; 1997 Sep; 43(9):1716-8. PubMed ID: 9299965
[TBL] [Abstract][Full Text] [Related]
15. Characterization and comparison of immune-depleted and hereditary factor-VII-deficient plasmas as substrate plasmas for factor VII assays.
Brandt JT; Triplett DA; Fair DS
Am J Clin Pathol; 1986 May; 85(5):583-9. PubMed ID: 3518398
[TBL] [Abstract][Full Text] [Related]
16. Studies on PIVKA VII.
Mariani G; Mazzucconi MG; Solinas S; Avvisati G; Chistolini A; Moretti T
Haemostasis; 1984; 14(3):238-43. PubMed ID: 6469099
[TBL] [Abstract][Full Text] [Related]
17. Mechanized amidolytic technique for determination of factor X and factor-X antigen, and its application to patients being treated with oral anticoagulants.
van Wijk EM; Kahlé LH; ten Cate JW
Clin Chem; 1980 Jun; 26(7):885-90. PubMed ID: 7379310
[TBL] [Abstract][Full Text] [Related]
18. Detection of protein C deficiency during oral anticoagulant therapy--use of the protein C:factor VII ratio.
Jones DW; Mackie IJ; Winter M; Gallimore M; Machin SJ
Blood Coagul Fibrinolysis; 1991 Jun; 2(3):407-11. PubMed ID: 1932526
[TBL] [Abstract][Full Text] [Related]
19. Chromogenic substrate spectrophotometric assays for the measurement of clotting function.
Aiyappa PA
Ann N Y Acad Sci; 1981; 370():812-21. PubMed ID: 6943978
[TBL] [Abstract][Full Text] [Related]
20. Experience with chromogenic substrates in studies of clotting and fibrinolytic systems.
Chmielewska J; Latallo ZS
Folia Haematol Int Mag Klin Morphol Blutforsch; 1982; 109(1):111-4. PubMed ID: 6177591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
